001     168147
005     20240229133559.0
024 7 _ |a 10.1038/s42255-021-00369-9
|2 doi
024 7 _ |a pmid:33758419
|2 pmid
024 7 _ |a altmetric:102035326
|2 altmetric
037 _ _ |a DKFZ-2021-00712
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Okun, Jürgen G
|b 0
245 _ _ |a Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes.
260 _ _ |a [London]
|c 2021
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1641383509_11683
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Division of Molecular Metabolic Control#EA:A170#
520 _ _ |a Both obesity and sarcopenia are frequently associated in ageing, and together may promote the progression of related conditions such as diabetes and frailty. However, little is known about the pathophysiological mechanisms underpinning this association. Here we show that systemic alanine metabolism is linked to glycaemic control. We find that expression of alanine aminotransferases is increased in the liver in mice with obesity and diabetes, as well as in humans with type 2 diabetes. Hepatocyte-selective silencing of both alanine aminotransferase enzymes in mice with obesity and diabetes retards hyperglycaemia and reverses skeletal muscle atrophy through restoration of skeletal muscle protein synthesis. Mechanistically, liver alanine catabolism driven by chronic glucocorticoid and glucagon signalling promotes hyperglycaemia and skeletal muscle wasting. We further provide evidence for amino acid-induced metabolic cross-talk between the liver and skeletal muscle in ex vivo experiments. Taken together, we reveal a metabolic inter-tissue cross-talk that links skeletal muscle atrophy and hyperglycaemia in type 2 diabetes.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Rusu, Patricia M
|b 1
700 1 _ |a Chan, Andrea Y
|b 2
700 1 _ |a Wu, Yuqin
|0 0000-0002-1762-1896
|b 3
700 1 _ |a Yap, Yann W
|b 4
700 1 _ |a Sharkie, Thomas
|b 5
700 1 _ |a Schumacher, Jonas
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Schmidt, Kathrin V
|b 7
700 1 _ |a Roberts-Thomson, Katherine M
|b 8
700 1 _ |a Russell, Ryan D
|b 9
700 1 _ |a Zota, Annika
|b 10
700 1 _ |a Hille, Susanne
|b 11
700 1 _ |a Jungmann, Andreas
|b 12
700 1 _ |a Maggi, Ludovico
|0 P:(DE-He78)b9f6e98404bac02f2318460886771357
|b 13
700 1 _ |a Lee, Young
|b 14
700 1 _ |a Blüher, Matthias
|0 0000-0003-0208-2065
|b 15
700 1 _ |a Herzig, Stephan
|0 P:(DE-He78)e527f794b23172e769c8904180546f57
|b 16
700 1 _ |a Keske, Michelle A
|b 17
700 1 _ |a Heikenwälder, Mathias
|0 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5
|b 18
|u dkfz
700 1 _ |a Müller, Oliver J
|b 19
700 1 _ |a Rose, Adam John
|0 P:(DE-He78)fcdc7b4207660a1372d0cd5491ad856e
|b 20
|e Last author
773 _ _ |a 10.1038/s42255-021-00369-9
|g Vol. 3, no. 3, p. 394 - 409
|0 PERI:(DE-600)2933873-6
|n 3
|p 394 - 409
|t Nature metabolism
|v 3
|y 2021
|x 2522-5812
909 C O |p VDB
|o oai:inrepo02.dkfz.de:168147
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)b9f6e98404bac02f2318460886771357
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)e527f794b23172e769c8904180546f57
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)fcdc7b4207660a1372d0cd5491ad856e
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-316
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Infections and cancer
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-08-23
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2020-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-08-23
920 1 _ |0 I:(DE-He78)F180-20160331
|k F180
|l F180 Chronische Entzündung und Krebs
|x 0
920 1 _ |0 I:(DE-He78)A170-20160331
|k A170
|l Molekulare Stoffwechselkontrolle
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F180-20160331
980 _ _ |a I:(DE-He78)A170-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21